A group of over 50 healthcare providers, including physicians, nurses and physician assistants, have come together to demand the federal government stop any action that would restrict access to lifesaving medications through personal prescription importation. In a letter sent to President Donald Trump, members of Congress and the Food and Drug Administration (FDA), the healthcare providers expressed their alarm over FDA’s action in Florida against offices that primarily serve older Americans who prefer in-person assistance with purchasing medications from Canada and other countries, rather than using an internet site.
As we leave 2017 behind, the crisis of high prescription drug prices continues to threaten the health and well-being of Americans who struggle to access life-saving medications. Millions of Americans are forced to choose between taking the medicine they need, paying the rent or buying food for their families; tens of millions don’t take prescribed medication; and federal and state budgets are overwhelmed. At Prescription Justice, we are dedicated solely to putting an end to this devastating crisis.
Last week, Gabriel Levitt, founder of Prescription Justice, published an Op-Ed in The Guardian about Alex Azar, President Trump’s nominee for Secretary of the Department of Health and Human Services (HHS). Mr. Levitt’s Op-Ed, Alex Azar is big pharma personified. He must not become US health secretary, underscores the urgent need for members of Congress to oppose Azar’s confirmation.
During recent testimony before the Senate Health, Education, Labor and Pension Committee hearing on Stabilizing the Affordable Care Act Marketplace, AARP became the largest consumer organization to publicly support the prescription drug policy solutions reflected in Prescription Justice’s policy platform. AARP supports commonsense policy reforms to allow Medicare to negotiate drug prices, end pay-for-delay deals that delay entry of generic drugs into the marketplace, and increase access to lower cost medications through safe prescription drug importation. As part of a larger set of priorities for protecting and strengthening the healthcare system, AARP boldly declared that any changes to the healthcare law must include solutions to address rising prescription drug costs.
Recently, The Hill featured the Op-Ed, A tale of two drug bills — one proposed bill will worsen the drug prices crisis, by Gabriel Levitt, President of Prescription Justice. Mr. Levitt’s Op-Ed provides an insightful look at legislation targeting two distinct public health problems, but only one has the capacity to inflict further devastation from the public health crisis that is high drug prices. The Synthetics Trafficking & Overdose Prevention Act of 2017 (STOP Act), introduced by Sen. Rob Portman (R- OH) aims to stop the flow of the highly addictive synthetic opioid fentanyl from coming into the U.S. by requiring the U.S. Postal Service (USPS) to obtain information about packages coming from foreign sources.